GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...

Read more: UKG's longtime CFO to step down, successor named Loesch was previously president and CCO at Intrommune Therapies ...

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

Gabapentinoids -- pregabalin and gabapentin -- were tied to increased hip fracture risk in older adults. Gabapentinoids -- ...

Emily Field from Barclays and Lance Wilks share insights on how RFK Jr.'s influence could affect stocks in the pharmaceutical and healthcare sectors, including companies like GSK, Sanofi, and Novo ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Haleon’s Robitussin and GSK’s RSV vaccine Arexvy. Robitussin had the lowest estimated national TV ad spend at $4.4 million.

The KSE-100 index of Pakistan Stock Exchange (PSX) lost on Tuesday more than 400 points, weighed down by institutional profit ...